Nerlynx
Neratinib Shows Promise in Certain Metastatic Breast Cancer Cases
A combination of neratinib, fulvestrant and trastuzumab showed encouraging clinical activity in patients with ...
MARCH 9, 2022
Nerlynx Granted Expanded Indication for Advanced/Metastatic HER2+ Breast Cancer
The FDA approved neratinib (Nerlynx, Puma) in combination with capecitabine for adults with advanced or metastatic ...
FEBRUARY 27, 2020
HER2 Inhibitor Yields Variable ORR Across Ca Types
Washington—In a trial that treated a variety of advanced solid tumors with a targeted HER2 inhibitor, the ...
JULY 19, 2017
Nerlynx Approved for HER2+ Breast Cancer
The FDA has approved neratinib for extended adjuvant therapy in early-stage HER2-positive breast cancer.
JULY 17, 2017
Load more